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Abstract
Objective: In this paper, we describe the main objec-
tives, the study design and the onset of the patient co-
hort of the German Competence Network for
HIV/AIDS (KompNet). Furthermore, we depict so-
ciodemographic and clinical baseline characteristics
and an estimation of the coverage and representativity
as to the composition of persons living with
HIV/AIDS (PLWHA) in Germany.
Methods: The KompNet cohort is an open, retrospec-
tive and prospective, multicenter, disease-specific and
nationwide cohort study that started gathering data in
June 2004. Semi-annually, follow up visits of the pa-
tients are documented, covering clinical and sociode-
mographic data. At enrolment and three years after-
wards, an EDTA-sample is taken; a serum-sample is
taken at every follow up visit.
Results: As of 14.9.2008, a total of 15,541 patients
were enrolled by 44 documenting sites. In September
2007, the cohort size was reduced to 10 outpatient
clinics and fifteen private practitioners, covering a total
of 9,410 patients. The documentation of these pa-
tients comprises 24,117 years of follow up-time since
enrolment (mean: 2.6 years), 62,862 person years in-
clusive data documented retrospectively on course of
HIV-infection and combined antiretroviral therapy
(cART, mean: 6.7 years). 1,008 patients (10.7%) were
lost to follow up and 175 (1.9%) died since enrolment.
84.9% of patients were men. Main risks of transmis-
sion were sex between men (MSM: 62.9%), heterosex-
ual contacts (18.4%), intravenous drug use (IVDU:
7.0%) and origin from a high prevalence country
(HPL: 5.2%). Mean age was 45 years.
Conclusion: The KompNet cohort covers about a
quarter of all patients being under treatment in Ger-
many. The composition of the cohort represents well
the most important risks of transmission in Germany.
The cohort contains a high proportion of patients be-
ing older than 49 years (28.1%). On basis of its com-
prehensive database and its biomaterials banks, the
KompNet cohort serves as an important instrument
to monitor and analyse the effects of combined anti-
retroviral therapy (cART) in Germany, interdigidating
basis, clinical and psychosocial research in view to
translational research.
Key words: Cohort Study, HIV/AIDS, Germany, Epi-
demiology, Clinical Research, Profile, Competence
Network HIV/AIDS
INTRODUCTION
HOW DID THE STUDY COME ABOUT?
In Germany, the first patients diagnosed with AIDS
were reported in 1982; their number rose distinctly
within the next years [1]. After introduction of cART,
the number of reported AIDS cases and deaths due
to AIDS in Germany decreased heavily, in coinci-
dence with an increasing HIV prevalence [2]. At the
end of 2008, the number of persons living with HIV
in Germany is estimated as 63,500, thereof 10,500
persons with AIDS [3]. The number of patients cur-
rently treated in Germany is estimated as 30,000 [4].
In 2008, 2,806 newly diagnosed HIV infections were
reported. This number grew constantly between 2001
and 2008 from 1,443 to 2,806 per year, with a flatten-
ing since 2006. The epidemiology of HIV/AIDS in
Germany is characterised by a high proportion of
men. Sex between men (MSM) is the main risk of
transmission, reflecting the characteristics of many
Western countries. MSM was risk of transmission in
65% of all reported newly diagnosed HIV-infections
in 2008, followed by heterosexual contacts (17%) and
persons originating from high prevalence countries
(12%) [2]. Compared to that, intravenous drug use
was of minor importance in Germany (5%). New in-
fections were diagnosed predominantly in urban areas.
AIDS cases declined from about 2,000 in 1995 to
about 550 in 2007, but a high number of unreported
cases is presumed [2]. The number of AIDS cases in
2008 is estimated as about 1,100. This high number is
supposed to be caused by late testing and a late start
of cART.
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last years, especially in Western countries. Not only
many new and potent drugs of well know substance
classes as protease inhibitors (PI), nucleoside reverse
transcriptase inhibitors (NRTI) and non-nucleoside re-
verse transcriptase inhibitors (NNRTI) were devel-
oped, which built the basis for cART since 1996. Also
complete new substance classes were developed and
mostly brought into standard medical practice, such as
fusion inhibitors, integrase inhibitors, co-receptor an-
tagonists and maturation inhibitors. Therewith, thera-
py of HIV/AIDS and its effects become complex
more than ever.
In Germany, direct costs of cART are covered by
health insurances. Medical care for HIV/AIDS in
Germany is provided by specialised outpatient clinics
as well as private practitioners. A high threshold re-
garding medical care in Germany are assumed regard-
ing special subpopulations, e.g. due to lacking health
insurance of people without legal residence permit or
because of cultural barriers [5, 6, 7, 8].
Due to this high complexity of the therapy of
HIV/AIDS and their circumstances, there was a big
need to establish an instrument to picture the reality
of cART and their effects in Germany. The KompNet
cohort of HIV-positive patients in Germany provides
data with national coverage and an extensiveness of
data acquisition that covers all described aspects of in-
terest [9, 10, 11,12].
In this profile, we bring out the rationale of the
KompNet cohort, its methods and organisation and
describe selected baseline characteristics of its patients
at state of date September 14th, 2008.
WHO SET UP THE KOMPNET COHORT AND HOW
IS IT FUNDED?
The KompNet cohort was set up and is conducted by
the Competence Network for HIV/AIDS. KompNet
was set up in 2002 as a scientific network to foster col-
laborations in the field of HIV/AIDS research and to
bring scientific results into practice. KompNet com-
bines expertise in different disciplines that are repre-
sented in four scientific boards: (1) basic research, (2)
clinical science, (3) social sciences and public health
and (4) gender and pediatric studies. These boards
generate scientific projects and evaluate submitted
project proposals from outside the network in close
collaboration. KompNet is governed by a steering
committee. Involving patient interests by including pa-
tient representatives into all governmental and scien-
tific bodies of the network and by spreading informa-
tion actively into the patient community is of high im-
portance within the network.
KompNet is funded by the Federal Ministry of Ed-
ucation and Research from its start in 2002 till August
2010. To ensure its scientific work and to sustain the
work with cohort data and biomaterials on a stable ba-
sis, KompNet is in transformation into a scientific
foundation. KompNet generates its financing out of
public funding predominantly and to a lower content
out of industrial collaborations, e.g. in the scope of
clinical studies.
The infrastructure of the KompNet cohort was es-
tablished since 2002, enrolment of the first patient
was in April 2004.
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Fig. 1. Current composition of documenting sites of the
KompNet cohort.
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KOMPNET COHORT?
The main objectives of the KompNet cohort study
are
• to establish a nationwide cohort of HIV-infected
patients attending outpatient clinics and private
practitioners specialised in treatment of
HIV/AIDS in Germany, as representatively as pos-
sible for the German situation,
• to collect a wide range of clinical and sociodemo-
graphic data as well as biomaterials regularly to fos-
ter clinical, laboratory and psychosocial research on
HIV/AIDS in Germany,
• to monitor the epidemiological composition of pa-
tients in German treatment institutions,
• to monitor on national level the course of HIV-in-
fection and the effects of cART, its side effects,
concomitant diseases and their treatment and to
analyse underlying mechanisms,
• to provide clinical data as well as biomaterials to
scientific projects from in- and outside the Komp-
Net and to collaborate with similar projects, on na-
tional and international level.
METHODS: HOW ARE DATA MEASURED?
The KompNet cohort is an open, retrospective and
prospective, multicenter, disease-specific and nation-
wide cohort, starting in 2004. The data come from and
are documented by clinical sites all over Germany
(outpatient clinics and private practitioners, Fig. 1).
Fig. 2. Modular structure of the KompNet cohort
The cohort consists of several modules, covering
different patient populations respectively clinical as-
pects (Fig. 2). The steering committee decides on the
composition of the variable sets applied to document
patient data within the different modules. Over time,
the variable sets were complemented, especially in re-
gard to enhance sociodemographic and behavioural
aspects.
Informed consent forms, specific for the basis
module, the children as well as the pregnancy cohort,
are used to explain the content of the cohort study,
comprehensively and patient-friendly. These forms
were approved by the ethic committee of every docu-
menting site. Before participation, each patient has to
sign the informed consent.
An extensive data protection concept was evaluated
and implemented, on basis of the “generic data pro-
tection concept” of the “Telematik-Plattform f￼r
medizinische Forschungsnetze in Deutschland” [13].
Every documenting site acts as its own ”data trustee”,
being the only place which holds both, the real name
of the patient and his unique patient identifier (PID)
of the specific site, used for identification in the scope
of the cohort documentation. This is because the
treating institution has the most comprehensive pro-
tection regarding confiscation of patient data. All oth-
er parts of the network dealing with data only use the
PID. This concept applies for all modules.
Data are documented via 2 follow up documenta-
tions per year. Documentation is done electronically
using the GCP- and FDA-approved software MACRO,
distributed by InferMed Ltd. Predefined case report
forms (CRFs) are used to document data in a highly
standardised way. All events occurring meanwhile are
documented via a variable number of “cyclic” CRFs.
Regarding the basis module, data are documented by
documentation officers employed by the documenting
sites. In the scope of the children and the pregnancy
cohort, data are gained by only one documentation of-
ficer travelling to the documenting sites. Data are
transferred from the documenting sites encrypted via
secured online channels to the central database.
Adult patients are documented within the “basis
module”. Inclusion criteria is age >17 years and a
signed informed consent. The documentation includes
a comprehensive set of variables, covering clinical and
laboratory data and a broad of sociodemographic and
behavioural details (s. box). Within the basis module, it
is possible to document patient data regarding the
time before enrolment into the cohort retrospectively,
if such data are available at the documenting site. For
this purpose, a core variable set is used covering data
on CDC-stage, CD4-cell-count, viral load and data on
cART, if the patient was treated.
A serum sample of 4ml is taken semi-annually at
every follow up visit, divided into 4 aliquots and
stored decentrally at the documenting site. An EDTA
sample of 9ml is taken at time of enrolment into the
cohort and again three years after enrolment, stored
centrally after DNA-extraction. Other biomaterials
like cerebral spin fluid, lymph node tissue, skin tissue,
and mucosa tissue are taken if respective examinations
are done, and only consented by the patient. Taking
and asservation of biomaterial samples follow detailed
standard operation procedures. In case a patient leaves
his/her treating institution and change to another that
is participating in the KompNet cohort, an ongoing
documentation is possible by passing on the specific
PID.
Data of HIV-infected and -exposed children are
surveyed within the children cohort. Inclusion criteria
are age <18 years and a signed informed consent.
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infected children as well as for parents of HIV-infect-
ed and HIV-exposed children. HIV-infected children
are followed up till leaving their paediatrician, HIV-ex-
posed children are followed up for 24 month. Data as
to the mother and the child (general anamnestic data,
HIV anamnesis, data on birth, clinical and laboratory
data on HIV and other diagnoses as well as data on
cART) are collected semi-annually (for details of doc-
umented variables, please see website of KompNet:
www.kompetenznetz-hiv.de). At enrolment, a 4ml
serum sample is taken from the child, afterwards 1ml
at each follow up visit. Also at enrolment, an EDTA
sample of 5ml is taken. Actually, eight specialised pae-
diatric HIV-centres participate in the children cohort.
Due to the documentation by one travelling documen-
tation officer, it is the aim to cover nearly all HIV-in-
fected and exposed children in Germany over time,
also being under medical care not at one of the eight
main documenting sites.
HIV-positive pregnant women are followed up for
the term of their pregnancy within the pregnancy co-
hort. Inclusion criteria are a HIV-infection, pregnancy
and a signed informed consent. Due to the short time
of pregnancy, the data are documented only once.
Data on sociodemography, gynaecological anamnesis,
the course of pregnancy, the delivery, HIV-anamnesis
as well as clinical findings and therapy of HIV and
concomitant diseases are collected (for details of doc-
umented variables, please see website). At enrolment, a
serum sample of 4ml and a 9ml sample of EDTA
blood are taken.
For both, the children and the pregnancy cohort, a
linkage of patient’s data to the basis module is possi-
ble, so children and pregnant women can be followed
up further, if attending one of the documenting sites
of the basis module.
Within specific modules, data on hepatitis and neu-
rological impairments of patients included in the basis
module can be collected, if existent (for details of
documented variables, please see website).
Data on resistant HIV of adult patients are report-
ed by nine laboratories within a resistance module
(Fig. 1). Only sequences of clinical routine testing are
collected. To link the sequence data to clinical data and
to ensure a maximum of data protection, a specific se-
quence number is used in addition to the PID of the
patient to indicate the specific sequence data. Also
here, the concept of the treating institution acting as a
“data trustee” is applied.
To assure the quality of documented data, several
monitoring processes are applied: while electronic data
entry, formal implausibilities are checked, documenta-
tion of affected data is denied. Via a central monitor-
ing process, more detailed aspects of plausibility of
the data are analysed constantly using a programming
of predefined criteria that are complemented steadily.
In addition, implausible data are identified while con-
ducting scientific analyses. All implausible data includ-
ing located duplicates are sent to the documenting
sites for correction. In case of locating systematic er-
rors in the documentation of a specific site, an on-site
monitoring can be conducted. There are trainings of
the documentation officers while implementing a doc-
umenting site, if a documentation officer changes, and
at specific meetings for all documentation officers; ad-
ditionally, a constant helpline via phone is in use.
RESULTS: HOW IS THE COHORT COMPOSED AND
WHO IS IN THE SAMPLE? 1
COMPOSITION
Enrolment of the first patient took place in April
2004. At start of documentation of data in June 2004,
the cohort consisted of 44 documenting sites. A total
of 15,541 patients had been registered in the cohort
over time. Due to a reduced financing of the cohort,
its size had to be scaled down to 26 documenting sites
in September 2007. In 2008, another documenting site
quit participation. Patients of the excluded document-
ing sites were no longer followed up since then.
Currently, there are 25 documenting clinical sites
(Fig. 1), covering 8,227 patients being reported as un-
der follow up2. Over time, 1,008 losses to follow up
(10.7%) and 175 deaths (1.9%) were registered. 561
patients (56.7% of all losses to follow up) were lost to
follow up due to a known change to another treating
institution not participating in the KompNet cohort.
Therewith, the 25 documenting sites cover a maxi-
mum number of 9,410 patients. These patients con-
tribute 24,117 person years since enrolment into co-
hort (mean: 2.6 years) and a total of 62,862 person
years including data documented retrospectively
(mean: 6.7 years). Due to the reduction of the cohort,
a preliminary stop of enrolment was realised in 2008
(Table 1). Since 2009, patients attending a document-
ing site therapy-na￯ve can be enrolled retrospectively
since January 2008 to ensure coverage of therapy
strategies being invented since then.
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Table 1. Number of enrolled patients, by year and type of
documenting site
25 actually 19 formerly
Year documenting sites documenting sites Total
2004 1,991 2,161 4,152
2005 3,966 2,851 6,817
2006 2,531 848 3,379
2007 876 271 1,147
2008 46 --- 46
Total 9,410 6,131 15,541
1 State of date: 14.9.2008. All data on which we refer to fur-
ther are reported by actually 25 documenting sites of the
basis module. Data of excluded sites are handled consis-
tent with the specifications given within the informed con-
sent by the specific patients: in nearly all cases, patients al-
lowed the KompNet to use their data further.
2 In the following, all analyses are made on basis of these
8,227 patients actively under follow up, if not mentioned
otherwise.
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exposed children using the children module started in
2008. Currently, a total of 206 HIV-exposed and
98 HIV-infected children were documented in five
of eight documenting sites. Range of age is 0-17
years. Central documentation of HIV-infected preg-
nant women will start in 2009 after completion
of ethics approval, ten documenting sites are affiliat-
ed. Within the neurology module, 92 patients were
documented. Documentation within the scope of
the resistance module was started in spring 2009, cov-
ering 631 sequences actually reported by nine labora-
tories.
SOCIODEMOGRAPHIC BASELINE
CHARACTERISTICS
With 84.9%, the cohort consists predominantly of
men. Men were older than women, regarding the
mean age (46 vs. 43 years, p<0.001) as well as the
mean age at HIV-diagnosis (36 vs. 32 years, p<0.001,
Table 2). The cohort comprises a high proportion of
patients ≥50 years (28.1%) The proportion of mi-
grants (patients with other origin than Germany)
was more as double as high in women as in men, with
special emphasis on Sub-Saharan countries (Table 3).
The four main risks of transmission within the co-
hort were MSM (62.9%), heterosexual contacts
(18.4%), IVDU (7.0%) and origin from a high preva-
lence country (5.2%), with distinct differences be-
tween sexes (Table 3). Men had more often a higher
vocational degree than women. Regarding their voca-
tional situation, a high proportion of men (37.0%) and
women (49.5%) were not employed.
CLINICAL BASELINE CHARACTERISTICS
28.4% of all patients were documented as positively
diagnosed with HIV before 1995. Proportions of men
and women regarding the CDC-stage were similar.
12.5% of all patients had an AIDS event before start-
ing cART.
Of 4,944 patients, the therapy status (therapy-na￯ve
or not) at start of documentation was given. 83.1%
were therapy-na￯ve at start of documentation, so the
complete cART-history of this subpopulation could
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Table 2. Actual baseline characteristics of patients of the KompNet cohort actually under follow up, by sex
Sex
male female p-value
Number
absolute1 6,976 1,241
% 84.9 15.1
Mean age (years, IQR) 46 (40-52) 43 (36-48) <0.001
Mean age at HIV-diagnosis (years, IQR) 36 (29-41) 32 (25-37) <0.001
Mean age at first documented date (years, IQR)2 39 (32-44) 36 (29-41) <0.001
Mean age at start of initial therapy (years, IQR, N = 3,119) 40 (33-46) 36 (29-41) <0.001
Highest vocational degree (N = 6,316) <0.001
Vocational training 42.7 38.4
Technical school 20.9 16.1
University 26.4 13.8
No vocational degree 7.7 28.1
Other 2.3 3.6
Vocational situation (N = 7,011) <0.001
Fully employed (> 34 h/week) 50.7 26.6
Part time work (15-34 h/week) 6.4 16.0
Employment by the hour (< 15 h/week) 3.5 5.8
Not employed 37.0 49.5
Other 2.4 2.1
Mean number of CD4-cell count at start of therapy 292 (159-389) 315 (155-423) 0.07
Mean HIV RNA copies at start of therapy (log, IQR)3 4.2 (3.4-5.2) 3.9 (3.0-4.9) 0.001
Mean number of CD4-cell count in actually treated patients (IQR) 538 (348-683) 518 (334-669) 0.06
Proportion of patients having viral load < detection limit
in actually treated patients (%) 78.6 76.3 0.1
Mean duration between first positive HIV-diagnosis and start of 3.3 (0.2-4.7) 3.7 (0.2-5.6) 0.06
initial cART (years, IQR)
1 Ten patients without data on sex, so N = 8,217.
2 Including retrospective data.
3 Viral loads of patients below detection limit were calculated as detection limit-1, depending on the specific test.
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py-na￯ve, 75.9% (abs.: 3,119) started with cART after-
wards: 27.4% remained initially treated, 72.6% had a
follow up-regimen.
The mean age at initiation of cART differed four
years between men and women (Table 2). The dura-
tion between the first positive HIV-diagnosis and start
of initial cART was 3.4 years, with no significant dif-
ferences between sexes. Also, we found no significant
differences regarding mean CD4-cell count at start of
initial therapy between men and women, mean num-
ber of HIV-RNA copies/ml at start of initial cART
differed slightly (Table 2). Mean number of CD4-cell
count in actually treated patients differed not signifi-
cantly between sexes, as well as the proportions of ac-
tually treated patients having a viral load below detec-
tion limit (Table 2).
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Table 3. Comparison of risk of transmission, age, origin and CDC-stage of patients of the KompNet cohort actually under follow
up, in comparison to newly diagnosed HIV-infections reported to the Robert Koch-Institute (aggregated 2004-2008), by sex
KompNet RKI
Sex Sex
male female p-value male female
Number
absolute 6,976 1,241 10,501 2,359
% 84.9 15.1 81.7 18.3
Risk of transmission1,2 (%)
MSM 74.1 --- <0.001 65.0 ---
Heterosexual contacts 11.2 58.6 <0.001 10.4 30.5
High prevalence country 2.5 20.3 <0.001 4.8 42.4
IVDU 5.1 17.6 <0.001 4.9 7.7
MTCT 0 0.1 0.05 0.5 2.5
Blood products 1.8 3.3 <0.001 00
Other 3.9 7.4 <0.001 --- ---
Not known 7.4 10.9 <0.001 14.3 16.9
Age (%)2,3 <0.001
< 20 years 0.0 0.1 3.0 8.2
20-24 years 0.7 2.3 7.0 12.1
25-29 years 3.1 5.4 15.6 23.3
30-39 years 20.9 33.6 36.2 32.4
40-49 years 45.8 38.9 26.8 14.6
50-59 years 19.3 13.5 7.5 6.2
≥ 60 years 10.2 6.2 3.9 3.2
Origin (%)4 <0.001
Germany 85.6 61.8 65.4 31.9
Western Europe 4.2 2.8 2.5 1.4
Central Europe 2.4 2.4 3.0 3.2
Eastern Europe 1.3 3.2 2.1 4.4
Sub-Saharan Africa 2.2 18.4 4.5 31.8
South/ South-East Asia 1.2 6.7 1.8 7.3
Latin America 1.2 1.8 1.4 0.8
Other 1.4 2.0 1.7 4.2
Not known 0.5 0.9 17.6 15.0
CDC-stage3 (%) 0.002
A 28.9 33.8 66.5 66.6
B 45.1 42.3 21.4 19.6
C 26.0 23.9 12.1 13.7
1 Multiple answers possible for KompNet cohort.
2 RKI data extracted using SurvStat[14].
3 RKI data: category “<20” includes also persons of 20 years.
4 RKI data: reports with given data on CDC-stage (Nmen=6,981, Nwomen=1,529)[15].
3 The therapy status at start of medical care at the actually
documenting site is not known for a subgroup of pa-
tients, e.g. because the patients were treated in another in-
stitution before attending the actually documenting site.
Missing data on therapy status at first documentation in
the cohort is under ongoing evaluation in collaboration
with the documenting sites.
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The KompNet conducts biomaterial banks that are
linked to the clinical data of the patient cohort. On
that basis, studies using clinical data in combination
with biomaterials can be set up, like pharmacogenetic
studies [16, 17, 18]. The current numbers of samples
are depicted in Table 4.
Table 4. Type of material, number of samples and type of
storage of KompNet biomaterial banks
Type of material Number of samples Type of storage
Serum 46,782 de-centrally
DNA 14,083 centrally
CSF 1,288 centrally
Skin tissue 2,500 centrally
Lymphnode tissue 120 centrally
COVERAGE AND REPRESENTATIVITY
Due to the specifics of the German health care ser-
vice, there are outpatient clinics as well as private prac-
titioners specialised in treatment of HIV-positive pa-
tients. The coverage of patients by outpatient clinics is
assumed as about 30%. Within the KompNet cohort,
ten documenting sites are outpatient clinics having
2,146 patients (26.1%) under follow up and fifteen
with 6,081 patients (73.9%), so this reflects well the
assumed coverage in Germany. The documenting sites
are located all over Germany and represent the epi-
demiological situation in Germany with high inci-
dences and prevalences in the urban areas of Berlin,
Frankfurt, Hamburg, Hannover, Rhine/Ruhr-area,
Stuttgart and Munich well (Fig. 1) [2]. Consisting of
about 8,000 patients, the KompNet cohort covers ap-
proximately a quarter of all treated HIV-positive pa-
tients in Germany, that are estimated as about 30,000
in 2008 [4].
There is no reliable data on sociodemographic and
clinical characteristics of the total population of pa-
tients treated with cART in Germany. As the best ap-
proximation to estimate the representativity of the
KompNet cohort regarding the German epidemiolog-
ical situation, we used baseline characteristics of per-
sons being reported as newly diagnosed for HIV to
the Robert Koch-Institute (RKI) mandatory between
2004 and 2008, the timeframe in which patients were
recruited for the KompNet cohort [14, 15].
Data of these two sources can only be compared in
a limited way, due to the different survey conditions.
The RKI data contain newly diagnosed HIV infections
in Germany, reported mandatory by broadly differing
kinds of testing institutions, as health care authorities,
AIDS help organisations, physicians etc. The Komp-
Net cohort only covers persons that are under medical
care. Due to this different recruitment conditions, dif-
ferences between this populations have to be assumed.
This applies especially to the stage of disease. We ex-
pect a substantial share of persons being newly diag-
nosed for HIV and not being in need of immediate
treatment. Of these, many could attend institutions of
medical care deferred and in a more progressed state
of infection. Consequentially, the KompNet cohort
covers higher proportions of patients in a more pro-
gressed stage of disease in comparison to the respec-
tive distribution of the RKI data (Table 3). This differ-
ence affects also the age distribution, with more elder-
ly persons in the KompNet cohort.
The proportion of risks of transmission in persons
newly diagnosed for HIV varied rather minor over
time, MSM remained the highest proportion, by far
[2]. Before this background, risks of transmission
should be distributed fairly equal in the KompNet co-
hort, despite the fact that a subpopulation of patients
enrolled in the KompNet cohort were diagnosed as
HIV-positive before 2004. There is one exception,
with special regard to women in the cohort: persons
with origin of a high prevalence country. Due to partly
lacking permit of residence or differing understanding
of disease, there are barriers of access to treating in-
stitutions for migrants. Additionally, there are difficul-
ties in recruiting migrants not originating from West-
ern countries for the cohort, being sceptical of partici-
pating in such a surveillance system often. Hence, the
proportion of migrants and patients coming from
high prevalence countries in the KompNet cohort is
only half of the proportion of the data on newly diag-
nosed infections, for both sexes (Table 3). The distrib-
ution of countries of origin reflects that as well (Table
3). The KompNet cohort includes nearly no patients
who were infected via mother to child transmission
(MCTC). One inclusion criteria of the cohort is age
>17 years, so there are very few eligible patients hav-
ing this risk of transmission.
Considering the different patterns between the pop-
ulations of persons being newly diagnosed for HIV
and being under medical care, the KompNet cohort
represents reasonably the distribution of PLWHA be-
ing under medical care in Germany. This applies to
central sociodemographic and clinical aspects as well
as to the geographical and professional composition
of the documenting sites.
WHAT ARE THE MAIN STRENGTHS AND
WEAKNESSES?
The KompNet cohort is the only nationwide operat-
ing cohort of HIV-positive patients in Germany col-
lecting also highly detailed data beyond the central as-
pects of HIV-infection and cART. Also its extensive
sociodemographic dataset and the availability of
linked biomaterials are valuable features. Estimating
the representativity of the KompNet cohort on basis
of existent data, the KompNet can be considered as
reasonably representative for the German situation,
with exception of the subgroup of migrants.
The KompNet cohort contains a high proportion
of older patients (28.1% ≥ 50 years). This is an impor-
tant condition to analyse the effect of cART in an age-
ing HIV-population. This topic becomes important
noticeably, especially in terms of concomitant diseases
in the course of HIV-infection, which are represented
by the variable set of the KompNet cohort broadly.
The collection of data and biomaterials of children
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very special clinical and treatment characteristics is an
essential tool to foster translational research and there-
with better therapy outcomes for these patients.
Via the PID and by contacting the documenting
site, it is possible to identify patients eligible for addi-
tional studies, e.g. clinical trials as well as sociodemo-
graphic or behavioural studies. Within the informed
consent, the patients have the possibility to state their
will whether they would like to be contacted for addi-
tional studies or not.
A weakness of the KompNet cohort is the labori-
ous documentation of highly detailed data, which
means an ongoing high effort in terms of workload
and financing to assure the quality of these data. Due
to the specifics of the German system of medical
care, it is not always possible to follow up a patient
who leaves a documenting site and is treated by an in-
stitution not participating in the cohort afterwards.
This applies especially to the urban areas of Germany
with higher numbers of institutions specialised in
HIV-treatment and shortens the follow up time of
these patients. Another weakness are the lacking docu-
menting sites in Eastern Germany, except Berlin.
Despite these limitations, the KompNet cohort
builds an important complement of the German sur-
veillance instruments in the field of HIV/AIDS.
HOW CAN I GET HOLD OF THE DATA AND
WHERE?
The KompNet can provide data and biomaterials of
its cohort to all scientists and institutions involved in
research in the scope of HIV/AIDS, on national and
international level. Scientists apply for data by submit-
ting a short study proposal (please see website for
form) that is evaluated and rated as to feasibility, scien-
tific impact and congruency with the aims of the
KompNet by its scientific boards, its steering commit-
tee and the central office. Potential collaborators are
invited to contact the cohort manager (email:
klaus.jansen@klinikum-bochum.de, website: kompe-
tenznetz-hiv.de).
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Items of the Basis-Module (variables are described without items regarding dates, units, frequency etc.)
Sociodemographic data
Vital status, sex, date of birth, place of residence, nationality, ethnicity, country of HIV infection, highest graduation,
vocational situation, monthly household netto income, health insurance status, partnership, living situation
Anamnesis
Family anamnesis: Diabetes mellitus, increased triglyceride, increased cholsterine, cardiovascular diseases, arterial ob-
structive disease, stroke
HIV anamnesis: date of last negative HIV test, date of first positive HIV diagnosis, HIV subtype, therapy status at en-
rolment (na￯ve, treated), assumed date of infection, risk of infection of enrolled patient, risk of infection of infecting
partner, infecting partner testes for HIV
Clinical findings
Height, weight, CDC-classification, weight loss, changes of body shape, clinical diagnoses (AIDS-associated, AIDS
defining, concomitant diseases), diarrhoea (stool frequency, medication and side effects)
Laboratory findings
HIV: CD3-/CD4-/CD8-T-lymphocytes, PCR
Haematology: status at blood withdrawal, haemoglobin, haematocrit, leucocytes, lymphocytes (%), neutrophiles (%),
thrombocytes, MCV
Clinical chemistry: blood glucose, HbA1c, C-peptide, total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cho-
lesterol, triglycerides, alc. phosphatase, cholinesterase, lactate
Further parameters of infection*: CMV IgG, Toxoplasma gondii IgG, TPHA, VDRL
Metabolic impairments*: rod neutrophiles, segmented neutrophiles, eosinophiles, basophiles, monocytes, lymphozytes,
CK, K, Ca, Na, urea, LDH, AST, ALT, γ-GT, total bilirubin, Lipase, creatinine, albumin, total protein, quick, CRP,
bone density, t value, z value
Gastro-enterology*: folate, beta-carotine, vitamine B12, vitamine D3, zinc, test for lactose tolerance, Schilling test, xylose
test
Microbiology*: material, pathogen, localisation
Medication
cART: substances, daily dose, frequency, application, first or proceeded prescription, change, interruption, side effects,
reason for change
constant and actual concomitant medications: substance, side effects
Behavioural data
Consumption of alcohol, amount and frequency (drinks/day), actual and past smoking habit (packyears)
* data on these variables are documented if the regarding examination was done. Otherwise, “not done” is documented.
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